SCHEMBL22323965

SCHEMBL22323965

COCOc1cc2c(=O)n(C)cnc2cc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
HDAC6 Q9UBN7 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
TNF P01375 3/20 0.39
IP6K1 Q92551 1/20 0.39
ACVR1 Q04771 2/20 0.36
HSD17B10 Q99714 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29447051 1.00 KDM4E (0.42) KDM4EHDAC6L3MBTL1ALDH1A1HPGD
SCHEMBL22323913 0.86 HDAC6 (0.48) KDM4EHDAC6L3MBTL1ALDH1A1HPGD
SCHEMBL29377697 0.86 HDAC6 (0.48) KDM4EHDAC6L3MBTL1ALDH1A1HPGD
SCHEMBL22323975 0.80 HDAC6 (0.44) HDAC6TNFHDAC3HDAC4HDAC1
SCHEMBL29447081 0.80 HDAC6 (0.44) HDAC6TNFHDAC3HDAC4HDAC1
SCHEMBL28689988 0.80 HDAC6 (0.48) KDM4EHDAC6L3MBTL1ALDH1A1HPGD
SCHEMBL28703844 0.79 HDAC6 (0.45) KDM4EHDAC6L3MBTL1ALDH1A1HPGD
SCHEMBL4728366 0.76 HDAC6 (0.59) KDM4EHDAC6L3MBTL1ALDH1A1HPGD
SCHEMBL28703804 0.76 L3MBTL1 (0.37) KDM4EHDAC6L3MBTL1ALDH1A1HPGD
SCHEMBL29447109 0.76 L3MBTL1 (0.37) KDM4EHDAC6L3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 KDM4E 2530/4885HDAC6 1838/4885L3MBTL1 176/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 KDM4E 2036/4885HDAC6 1714/4885L3MBTL1 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.